Euthyroid Sick Syndrome
Conditions
Interventions
thyroid hormone replacement therapy group:Oral administration of 5 ug/kg/day of thyroid hormone tablets 24h postoperatively for 5 consecutive days
Placebo-Controlled Group:Oral administration of a placebo (milk tablets of the same appearance) 24h postoperatively for 5 consecutive days
Sponsors
Children's Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: (1) Children under one year of age, both genders are eligible; (2) Diagnosed with congenital heart disease requiring surgery under extracorporeal circulation, can be combined with pulmonary arterial hypertension or valvular regurgitation; (3) Preoperative thyroid hormone levels are normal, ultrasound shows no organic lesions, no thyroid tablets were taken preoperatively, and postoperatively developed Euthyroid Sick Syndrome (ESS) in children; (4) The guardians of the child understand the nature of this trial and agree to participate, voluntarily sign the informed consent form approved by the ethics committee, and agree to accept the postoperative treatment plan and follow-up requirements.
Exclusion criteria
Exclusion criteria: (1) The disease suffered by the patient will cause difficulties in evaluation (such as malignant tumors, chromosomal abnormalities, airway deformities, renal dysfunction, gastrointestinal deformities, severe metabolic diseases, etc.); (2) Preoperative myocardial dysfunction, acidosis, shock, etc.; (3) Death within 24 hours postoperatively or during the surgery; (4) Postoperative extracorporeal membrane oxygenation (ECMO) support; (5) History of previous cardiac surgery; (6) The researcher judges that the patient's compliance is poor and cannot complete the study as required (including but not limited to those with obvious mental disorders, epilepsy patients, and others who are unable to act or have cognitive abilities); (7) Social assistance personnel and non-Chinese citizens.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative left ventricular ejection fraction;the length of hospitalization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vasoactive-inotropic score;mechanical ventilation time;length of CCU stay;Whether Low Cardiac Output Syndrome (LCOS) occurs;whether Compartmental Fluid Accumulation occurs;In-hospital mortality ; | — |
Countries
China
Contacts
Public ContactZou Liang; Mo Xuming
Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University
Outcome results
None listed